In re Patent Application

Group Art Unit:

Examiner:

Atty Dkt. 117-358 M# C#

ED STATES PATENT AND TRADEMA

VALLANCE et al.

Serial No. 09/889,733

Filed: September 14, 200

Date: March 26, 2003

DIMETHYLARGININE DIMETHYLAMINOHYDROLASES (AS AMENDED) Title:

Assistant Commissioner for Patents Washington, DC 20231

Sir:

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

☐ Correspondence Address Indication Form Attached.

Fees are attached as calculated below: minus highest number Total effective claims after amendment 0 0.00 (at least 20) =\$ 18.00 \$ previously paid for 20 Х Independent claims after amendment minus highest number \$ 84.00 0.00 previously paid for 3 (at least 3) =0 \$ If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) \$ 0.00 Petition is hereby made to extend the current due date so as to cover the filing date of this \$ paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months) 0.00 Terminal disclaimer enclosed, add \$ 110.00 \$ 0.00 First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00) \$ 0.00 Please enter the previously unentered . filed Submission attached Subtotal \$ 0.00 If "small entity," then enter half (1/2) of subtotal and subtract -\$ 0.00 Applicant claims "small entity" status. Statement filed herewith Rule 56 Information Disclosure Statement Filing Fee (\$180.00) \$ 0.00 Assignment Recording Fee (\$40.00) \$ 0.00 Other: 0.00 TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:

D STATES PATENT AND TRADEMAR

In re Patent Application of

Atty Dkt. 117-358

C#

VALLANCE et al.

Group Art Unit:

Serial No. 09/889,733

Examiner:

Filed: September 14, 2001

Date: March 26, 2003

Title:

DIMETHYLARGININE DIMETHYLAMINOHYDROLASES (AS AMENDED)

Assistant Commissioner for Patents Washington, DC 20231

Sir:

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

F s ar attached as calculated below: Total effective claims after amendment 0 minus highest number previously paid for 20 (at least 20) = 0 x \$ 18.00	\$	0.00
Independent claims after amendment 0 minus highest number previously paid for 3 (at least 3) = 0 x \$ 84.00	\$	0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$410.00/2 months; \$930.00/3 months)	\$	0.00
Terminal disclaimer enclosed, add \$ 110.00	\$	0.00
☐ First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$750.00) ☐ Please enter the previously unentered , filed ☐ Submission attached	\$	0.00
Subtotal	\$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. Statement filed herewith	-\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00
Assignment Recording Fee (\$40.00)	\$	0.00
Other:		0.00
TOTAL FEE ENCLOSED	\$	0.00

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.


1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:



Commissioner for Patents, Box PCT Umterf States Patent and Tradamork Office Washington, D.C. 20231

U.S. APPLICATION NUMBER	R NO. FIRST NAMED APPLICAN	Γ	ATTY	. DOCKET NO.	
09/889,733	Patrick John Thompson Va	allance	ance 117-358		
		INTERNATIONAL APPLICATION NO.			
	DOCKETED	PC	PCT/GB00/00226		
Nixon & Vanderhye	D001(2122	I.A. FILING	DATE	PRIORITY DATE	
8th Floor 1100 North Glebe Road	CLT/MATTER # 117.358	01/26/2	000	01/26/1999	
Arlington, VA 22201-4714	MAIL DATE	371 FORMA	LITIES L	ATION NO. 9066 ETTER	

Date Mailed: 02/26/2003

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- · Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

Applicant's response filed 09/14/2001 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 09/19/2001 have not been completed.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- FIGURES 1,4 AND 6 CONTAIN NUCLEIC ACID SEQUENCES THAT ARE NOT DESCRIBED IN THE SEQUENCE LISTING. PAGES 32,33,35, ET AL.CONTAIN NUCLEIC ACID SEQUENCES THAT ARE NOT DESCRIBED IN THE SEQUENCE LISTING.
- APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase Patentin Software, call (703) 306-2600
 - For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

ANITA D JOHNSON

Telephone: (703) 305-3661

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/889,733	PCT/GB00/00226	117-358

FORM PCT/DO/EO/916 (371 Formalities Notice)

*Total of

PTO/SB/121 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ORRESPONDENCE **ADDRESS INDICATION FORM**

Addr ss t:

Assistant Commissioner for Patents Box CN Washington, DC 20231

Customer Number: 23117 Place Customer Number Bar Label Here → Type Customer Number here Request for Customer Number (PTO/SB/125) submitted herewith. in the following listed application(s) or patent(s): Patent Number Patent Date U.S. Filing
Request for Customer Number (PTO/SB/125) submitted herewith. in the following listed application(s) or patent(s):
in the following listed application(s) or patent(s):
in the following listed application(s) or patent(s):
Patent Date U.S. Filling
Tatorit Number
(if appropriate) Application Number (if appropriate) Date 09/889,733 September 14, 2001
(check one)
Typed or Printed Name Applicant or Patentee
Signature Assignee of record of the entire interest. Statement under 37 C.F.R.
Date March 26, 2003 3.73(b) is enclosed. (Form PTO/SB/96)
Address of signer: 1100 North Glebe Road, 8 th Floor Attorney or Agent of record Arlington, VA 22202
32,955 (Reg. No.)
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.*

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS: SEND TO: Assistant Commissioner of Patents, Box CN, Washington, DC 20231.

forms are submitted.